Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
Ligand Pharmaceuticals announced it will acquire XOMA Royalty for $39.00 per share in cash, representing a total equity value of approximately $739 million and a 14% premium to XOMA's 30-day volume weighted average price. The transaction, expected to close in Q3 2026, is immediately accretive and prompted Ligand to raise its 2026 revenue guidance to $270 million to $310 million and adjusted EPS guidance to $8.50 to $9.50.
Key figures
- Guidance
- 2026 revenue $270 million to $310 million (previously $245 million to $285 million); 2026 adjusted EPS $8.50 to $9.50 (previously $8.00 to $9.00); expected 2027 adjusted EPS accretion of $1.50 per share
- Deal Value Usd
- 739000000
- Premium to vwap
- 14%
- Acquisition price per share
- 39
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.